Announcement PDF argoinvestments.com.au | 1 Net tangible asset (NTA) backing per share 31 August ex dividend^ 31 July cum dividend NTA per share1 $10.96 $11.07 NTA per share after unrealised tax provision2 $9.29 $9.41 Market commentary Australian shares rose for the fourth consecutive month in August, with the S&P/ASX 200 Accumulation Index up +1.5%. Gains were led by Resources, especially gold miners (+29%), and Health Care, boosted by CSL (nearly +40%), reflecting a rebound in investor confidence. In contrast, Consumer Discretionary was the worst-performing sector as recent interest rate rises and tax changes continued to dent household sentiment. The August corporate reporting season was solid, with companies generally exceeding earnings and dividend expectations. However, outlook commentary was sparse, with relatively few companies willing or able to provide earnings guidance given the considerable global uncertainty, including the upcoming US mid-term elections, the prospect of US rate hikes and the ongoing war in the Middle East. $m % BHP 707.5 8.4 Macquarie Group 586.9 6.9 Rio Tinto 390.3 4.6 CBA 373.5 4.4 Wesfarmers 310.2 3.7 ANZ 296.7 3.5 Westpac 290.2 3.4 CSL 266.8 3.2 Santos 240.2 2.8 Aristocrat Leisure 226.2 2.7 NAB 224.0 2.6 Telstra 221.0 2.6 Technology One 210.2 2.5 QBE Insurance 177.9 2.1 Computershare 174.9 2.1 Origin Energy 161.6 1.9 Woodside Energy 138.5 1.6 APA 137.2 1.6 Woolworths 136.2 1.6 Transurban 121.6 1.4 Top 20 equity investments 5,391.6 63.6 Cash 139.6 1.7 Portfolio Sector diversification NTA & Investment Update August 2026 Top 20 investments ƺ After all costs, including any tax payable. Ʊ As required under the ASX Listing Rules, theoretical NTA per share after providing for estimated tax on unrealised gains/losses in the portfolio. That is, after tax that may arise if the entire portfolio was sold. ^ These figures are after provision for the final dividend of 20.0 cents per share. argoinvestments.com.au | 2 This report has been prepared as general information only and is not intended to provide financial advice or take into account your objectives, financial situation or needs. You should consider, with a financial adviser, whether the information is suitable for your circumstances before making any investment decisions. Past performance is no guarantee of future results. This announcement is authorised by Tim Binks, Company Secretary. Argo Investments Limited ACN 007 519 520 Shareholder benefits Low-cost, internally managed Internal management structure ensures low operating costs and no external fees Long-term and proven investment approach Resilience and growth through various market cycles and conditions for 80 years Experiencedboardandmanagement Highly experienced board and management team with strong governance and conservative culture Fully-franked, sustainable dividends Dividends paid every year since inception in 1946 and fully franked since 1995 Strong balance sheet with no debt A strong balance sheet and no debt allows a long-term approach to investing Diversified and administratively simple Exposure to a diversified portfolio of Australian equities through a single ASX trade About us ASX code ARG Founded 1946 Total assets $8.2bn Shareholders 85,200 Dividend yield^ 4.1% MER 0.14% ^ Historical yield of 5.9% (including franking) based on dividends paid/declared over the last 12 months. At a glance How to invest We are listed on the Australian Securities Exchange (ASX) under the ASX code ‘ARG’. To become a shareholder, simply buy shares through your stockbroker, online broker, financial adviser or platform. Company objective Maximise long-term shareholder returns through reliable fully franked dividend income and capital growth. Share registry enquiries BoardRoom Pty Ltd 1300 350 716 investorserve.com.au argo@boardroomlimited.com.au Company overview One of Australia’s oldest and largest listed investment companies (LICs), Argo actively manages a diversified portfolio of Australian shares with a low-cost, internally managed business model. Argo applies a conservative, long-term investment approach which has proven resilient since 1946.